Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation | Zendy

Laura Gioia | Zendy; Mahesh Kate | Zendy; Leka Sivakumar | Zendy; Dulara Hussain | Zendy; Hayrapet Kalashyan | Zendy; Brian Buck | Zendy; Miguel Bussière | Zendy; Thomas Jeerakathil | Zendy; Ashfaq Shuaib | Zendy; Derek Emery | Zendy; Kenneth Butcher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation

Author(s) -

Laura Gioia,

Mahesh Kate,

Leka Sivakumar,

Dulara Hussain,

Hayrapet Kalashyan,

Brian Buck,

Miguel Bussière,

Thomas Jeerakathil,

Ashfaq Shuaib,

Derek Emery,

Kenneth Butcher

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.013491

Subject(s) - medicine , rivaroxaban , stroke (engine) , interquartile range , asymptomatic , magnetic resonance imaging , cardiology , atrial fibrillation , surgery , anesthesia , warfarin , radiology , mechanical engineering , engineering

Early anticoagulation after cardioembolic stroke remains controversial because of the potential for hemorrhagic transformation (HT). We tested the safety and feasibility of initiating rivaroxaban ≤14 days after cardioembolic stroke/transient ischemic attack.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research